CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics
CASI Price/Volume Stats
| Current price | $2.43 | 52-week high | $8.48 |
| Prev. close | $2.25 | 52-week low | $1.85 |
| Day low | $2.28 | Volume | 13,100 |
| Day high | $2.50 | Avg. volume | 174,009 |
| 50-day MA | $4.12 | Dividend yield | N/A |
| 200-day MA | $4.09 | Market Cap | 32.56M |
CASI Stock Price Chart Interactive Chart >
CASI Pharmaceuticals, Inc. (CASI) Company Bio
CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.
Latest CASI News From Around the Web
Below are the latest news stories about CASI PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CASI as an investment opportunity.
Analysts Expect Breakeven For CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Before LongCASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) is possibly approaching a major achievement in its business, so we would... |
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended September 30, 2023. |
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPACASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas). The China National Medical Products Administration (NMPA) has granted market approval for Juventas' investigational cell therapy, Inaticabtagene Autoleucel (CNCT 19), for the treatment of relapsed and refractory B-cell acute lymph |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about! |
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the quarter ended June 30, 2023. |
CASI Price Returns
| 1-mo | -20.59% |
| 3-mo | -60.16% |
| 6-mo | -26.81% |
| 1-year | -20.07% |
| 3-year | -85.54% |
| 5-year | -92.72% |
| YTD | -66.06% |
| 2023 | 300.00% |
| 2022 | -77.63% |
| 2021 | -72.88% |
| 2020 | -4.53% |
| 2019 | -23.13% |
Loading social stream, please wait...